YTEN stock: buy or sell?
September 20th, 2019
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States.
Should I buy YTEN stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Yield10 Bioscience stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Yield10 Bioscience stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we detected 6 ratings published for YTEN stock in the last 30 days. The general sentiment of these ratings is bullish for YTEN stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
YTEN stock analysis
Yield10 Bioscience shares slipped -3.28% to $0.59 today.
Yield10 Bioscience shares slipped -3.28% to $0.59 today. YTEN marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $0.66 would break this short term down trend and open possibilities for reversing this situation.
Shares of Yield10 Bioscience collapsed a scary -9.23% this week. Early August YTEN skyrocketed a dazzling 9.38% in just one week.
Yield10 Bioscience slid through the support line what triggered further losses.
YTEN stock price history
YTEN stock went public on November 10th, 2006 with a price of $855.001. Since then, YTEN stock lost a -99.90%, with a yearly average of -8.30%.
1: Adjusted price after possible price splits or reverse-splits.
YTEN stock historical price chart
YTEN stock reached 52-week highs on March at $1.77, and all-time highs 2007-10-30 with a price of 1785.6.
YTEN stock price target is $4.30Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' YTEN stock price predictions in the hope that they will be met as they may be wrong and not met. We found 4 price predictions for YTEN stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-26||Maxim Group||Set Price Target||n/a||$5.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter posting its last earnings report on March, Yield10 Bioscience . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Yield10 Bioscience annual sales plummed a hair-raising -41.10% to $0.56 million dollars from $0.94 marked in 2017. Likewise, its earnings margin (compared to revenues) collapsed to -1,649.28%, that is $-9.17 million.
|2013||$5.39 M||-||$-30.51 M-566.0%||-|
|2014||$2.80 M||-48.05%||$-29.53 M-1054.8%||-3.20%|
|2015||$2.59 M||-7.36%||$-23.68 M-912.9%||-19.82%|
|2016||$1.16 M||-55.32%||$-7.60 M-656.1%||-67.89%|
|2017||$0.94 M||-18.55%||$-9.40 M-995.3%||23.57%|
|2018||$0.56 M||-41.10%||$-9.17 M-1649.3%||-2.41%|
Quarterly financial resultsYield10 Bioscience posted $0.14 M in revenues for 2018-Q4, a 77.63% up compared to previous quarter. Reported quarter income marked $-1.86 M with a profit margin of -1,377.78%. Profit margin skyrocketed a 2,082.75% compared to previous quarter when profit margin was -3,460.53%. When comparing turnover to same quarter last year, Yield10 Bioscience sales marked an outstanding increase and climbed a 29.81%.
|2017-Q1||$0.32 M||-||$-2.09 M-645.1%||-|
|2017-Q2||$0.29 M||-9.57%||$-2.73 M-931.7%||30.62%|
|2017-Q3||$0.22 M||-23.89%||$-2.03 M-908.1%||-25.82%|
|2017-Q4||$0.10 M||-53.36%||$-2.55 M-2453.8%||26.02%|
|2018-Q1||$0.06 M||-42.31%||$-2.29 M-3816.7%||-10.27%|
|2018-Q2||$0.29 M||375.00%||$-2.39 M-838.6%||4.37%|
|2018-Q3||$0.08 M||-73.33%||$-2.63 M-3460.5%||10.04%|
|2018-Q4||$0.14 M||77.63%||$-1.86 M-1377.8%||-29.28%|
Yield10 Bioscience ownershipWhen you are planning to buy shares of a company, it's worth to have a look its ownership structure.
Yield10 Bioscience shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 29.65% of all shares.
In case of Yield10 Bioscience stock, 7.26% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for YTEN stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$7.4 M||$147.9 B||$22.8 B||$2.4 B||$1.8 B|
|Total shares||12.5 M||1,770.0 M||557.0 M||76.9 M||40.2 M|
|Float shares||9.3 M||1,750.0 M||554.3 M||76.0 M||39.9 M|
|- Institutional holdings (%)||7.3%||76.5%||80.4%||95.7%||97.5%|
|- Insider holdings (%)||29.6%||0.7%||0.3%||1.1%||0.6%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$0.59 - $0.64|
|Average true range||$0.05|
|50d mov avg||$0.84|
|100d mov avg||$0.88|
|200d mov avg||$0.99|
Yield10 Bioscience performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We selected , Archer-Daniels-Midland, PolyOne, Trinseo and Westlake Chemical as the bechmarking frame for Yield10 Bioscience stock.